Published in Pharma Law Weekly, June 1st, 2004
The trial is being conducted in the United States under a U.S. Food and Drug Administration (FDA) Investigational New Drug Application (IND). CRX-675 is a member of Corixa's family of proprietary compounds that interact with toll-like receptor 4 (TLR4).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly